FDA Commissioner provides update on product quality maintenance

US Food and Drug Administration Commissioner Scott Gottlieb has issued a statement detailing steps his agency plans to take to maintain product quality and transparency at foreign drug manufacturing facilities.

Noting a shift to overseas production of US goods in the early 2000s, he said the FDA has in that time established a framework to help ensure standards were maintained, including a system of inspections and surveillance.

Building on this, Dr Gottlieb said that to add greater transparency around the site selection model, the FDA will publish its internal policy guiding the way sites are prioritized and scheduled for surveillance inspections.